Adverse cardiovascular events in rheumatoid arthritis patients treated with JAK inhibitors: An analysis of postmarketing spontaneous safety reports
Adam Goldman, Bat-El Lugassy Galper, Amit Druyan, Chagai Grossman, Κassem Sharif, Liran Shechtman, Yonatan Moshkovits, Adi Lahat, Ilan Ben‐Zvi
Topics & Concepts
MedicineTofacitinibTocilizumabPostmarketing surveillanceRheumatoid arthritisInternal medicineAdverse effectPeripheral edemaPharmacovigilanceRheumatoid Arthritis Research and TherapiesPharmacovigilance and Adverse Drug ReactionsInterstitial Lung Diseases and Idiopathic Pulmonary Fibrosis